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Elongin A increases the rate of RNA polymerase II
(pol II) transcript elongation by suppressing transient
pausing by the enzyme. Elongin A also acts as
a component of a cullin-RING ligase that can target
stalled pol II for ubiquitylation and proteasome-
dependent degradation. It is not known whether
these activities of Elongin A are functionally interde-
pendent in vivo. Here, we demonstrate that Elongin
A-deficient (Elongin A/) embryos exhibit abnormal-
ities in the formation of both cranial and spinal nerves
and that Elongin A/ embryonic stem cells (ESCs)
show a markedly decreased capacity to differentiate
into neurons. Moreover, we identify Elongin A muta-
tions that selectively inactivate one or the other of
the aforementioned activities and show that mutants
that retain the elongation stimulatory, but not pol II
ubiquitylation, activity of Elongin A rescue neuronal
differentiation and support retinoic acid-induced up-
regulation of a subset of neurogenesis-related genes
in Elongin A/ ESCs.
INTRODUCTION
The synthesis of mRNA in eukaryotes is regulated by the con-
certed action of a set of transcription factors that control the
activity of RNA polymerase II (pol II) during the initiation and elon-
gation stages of transcription. Although the initiation stage of
transcription by pol II was long thought to be the primary site
for regulation, a growing body of evidence indicates that tran-
script elongation can also be rate limiting and is an importantCell Retarget for gene regulation by a diverse collection of elongation
factors that promote efficient elongation of transcripts by pol II
in vitro (Saunders et al., 2006). Elongin is a member of a family
of elongation factors that can increase the overall rate of RNA
chain elongation by decreasing the frequency and/or duration
of transient pausing by pol II as it traverses the DNA template
(Conaway et al., 2000; Shilatifard et al., 2003).
Elongin is a three-subunit complex composed of the transcrip-
tionally active Elongin A subunit and two positive regulatory sub-
units, Elongins B and C, which share sequence similarity with
ubiquitin and with the Skp1 subunit of SCF ubiquitin ligases,
respectively (Aso et al., 1995). Elongin A binds Elongins B and
C through a sequence motif referred to as the BC box (Aso
et al., 1996). Elongins B andC are subunits not only of the Elongin
complex but are alsomembers of a large family of Cullin 2 (Cul2)-
or Cullin 5 (Cul5)-based ubiquitin ligases, in which a BC box con-
taining substrate recognition subunit is linked through theElongin
BC heterodimer to a subcomplex composed of Cul2 or Cul5 and
either of the small RING finger proteins Rbx1 or Rbx2. We and
others have shown recently that Elongin A can act as the BC
box substrate recognition subunit of a Cul5- and Rbx2-contain-
ing ubiquitin ligase that ubiquitylates the largest subunit of pol II
(Rpb1) (Yasukawa et al., 2008; Harreman et al., 2009).
Although mammalian Elongin A is not essential for cell viability
in vitro, Elongin A is essential in vivo. Elongin A-deficient (Elongin
A/) mouse embryos exhibit developmental abnormalities in-
cludingcentral nervous system (CNS) anomalies anddiebetween
days 10.5 and 12.5 of gestation (Miyata et al., 2007). In addition,
the Elongin A ortholog in Drosophila has been shown to be
required for optimal expression of the heat shock gene HSP70
and several Hox genes, including Ultrabithorax and Abdominal-
B (Gerber et al., 2005; Chopra et al., 2009). Because Rpb1 ubiq-
uitylation following pausing or arrest of pol II is now believed to
be one mechanism that helps to ensure the overall efficiency ofports 2, 1129–1136, November 29, 2012 ª2012 The Authors 1129
Figure 1. Elongin A/ Embryos and ESCs
Exhibit Impaired Neuronal Differentiation
(A) Neurons in E10.5 wild-type and Elongin A/
embryos were visualized by whole-mount immu-
nostaining using anti-neurofilament antibody 2H3.
Arrowheads indicate DRG. III, oculomotor nerve;
V, trigeminal ganglion; VII, facial ganglion; VIII,
vestibulocochlear ganglion; IX, glossopharyngeal
nerve; X, vagal nerve; XI, accessory nerve. Scale
bars, 500 mm.
(B) Immunostaining of transverse sections through
the trigeminal region of E10.5 wild-type and Elon-
gin A/ embryos using anti-bIII-tubulin antibody.
Arrowheads indicate trigeminal ganglion. Scale
bars, 100 mm.
(C) Whole-mount in situ hybridization of E9.5–
E10.5 wild-type and Elongin A/ embryos using
indicated cRNA probes. S, somites; OV, otic
vesicle; IX, glossopharyngeal ganglion; X, vagal
ganglion. Scale bars, 500 mm.
(D) EBs derived from Elongin A+/+ and Elongin A/
ESCs were grown in the absence or presence of
RA. Paraffin sections were stained with anti-nestin
or anti-bIII-tubulin antibody.
(E) Elongin A+/+ ESCs and Elongin A/ ESCs were
subjected to 4/4+ protocol for EB formation, and
dissociated EBs were plated on a poly-L-lysine/
gelatin-coated chamber slide for neuronal differ-
entiation. Cells were fixed and double stained with
anti-bIII-tubulin and anti-MAP2 antibodies. Total
cells were viewed by staining of nuclei with DAPI.
The corresponding phase-contrast images are
also shown.
(F and G) TUNEL analysis (F) and staining with anti-
Ki67 antibody (upper panels) and with hematoxylin
(lower panels) (G) of sections of Elongin A+/+ and
Elongin A/ EBs.
See also Figure S1.transcript elongation (Svejstrup, 2007), it remains unclear which
activity of Elongin A, transcriptional elongation or Rpb1 ubiquity-
lation, in fact plays a more crucial role in gene expression in vivo.
In this study, we demonstrate that Elongin A/ mouse embryos
and Elongin A/ embryonic stem cells (ESCs) exhibit impaired
neuronal development and differentiation, respectively. Further-
more, we show that Elongin A mutants that are defective in
Rpb1 ubiquitylation but retain the ability to stimulate transcript
elongation can rescue neuronal differentiation and retinoic acid
(RA)-induced upregulation of a subset of neurogenesis-related
andother genes inElonginA/ESCs.Taken together, our results
suggest that the elongation stimulatory activity of mammalian
Elongin A plays a crucial role in the timely expression of a subset
of genes required for neuronal development.1130 Cell Reports 2, 1129–1136, November 29, 2012 ª2012 The AuthorsRESULTS
Elongin A/ Embryos Exhibit
Severe Abnormalities in Both the
Cranial and Spinal Nerves
We have previously shown that Elongin
A/ embryos die between days 10.5
and 12.5 of gestation. Elongin A/ em-bryos exhibit poor development of the CNS accompanying
significantly reduced thickness and cellularity of the cranial and
spinal neuroepithelium (Miyata et al., 2007). In addition, some
but not all Elongin A/ embryos are smaller and developmen-
tally delayed in comparison to their wild-type or Elongin A+/
littermates.
To characterize further the neural defects in Elongin A/
embryos, we evaluated embryonic nervous systemdevelopment
in size- and stage-matched wild-type and Elongin A/ embryos
via whole-mount immunostaining of neurofilaments at E10.5. As
shown in Figure 1A, the oculomotor nerve (III) was missing in the
Elongin A/ embryos. The formation of the trigeminal (V) and
facial/vestibulocochlear (VII/VIII) ganglia, and the neurite out-
growth of glossopharyngeal (IX), vagal (X), and accessory (XI)
nerves were markedly impaired in Elongin A/ embryos com-
pared to wild-type embryos. In addition, outgrowth of spinal
nerves and dorsal root ganglia (DRG) was severely disrupted in
Elongin A/ embryos. To clarify the mechanism underlying
these defects, cell proliferation and apoptosis in embryos were
examined by phospho-Histone H3 staining and cleaved cas-
pase-3 and TUNEL staining, respectively. The trigeminal ganglia
of Elongin A/ embryos were much smaller compared with
those of wild-type littermates, as indicated by the expression
of bIII-tubulin, a representative marker of mature neurons (Fig-
ure 1B). No significant difference in phospho-Histone H3 staining
was observed in the trigeminal ganglia between wild-type and
Elongin A/ embryos, whereas an increase in the number of
both cleaved caspase-3+ and TUNEL+ cells was only observed
in Elongin A/ embryos (Figures S1A and S1B), indicating that
these defects are not due to a decrease in proliferation but are
at least in part due to an increase in cell death. Similar observa-
tions were made for facial/vestibulocochlear, glossopharyngeal,
and vagal ganglia (data not shown).
Cranial ganglia are formed by contribution of two ectodermal-
origin cell types, neural crest and ectodermal placodes, whereas
DRG are formed exclusively from trunk neural crest cells. In an
effort to determine whether the neurons of neural crest origin
or of placodal origin are differentially affected in the cranial
ganglia of Elongin A/ embryos, we examined the expression
of neural crest and placode lineage-specific marker genes at
appropriate stages. We analyzed Sox10 expression at E9.5 (23
somites), a time point when Sox10 is specifically expressed in
neurogenic neural crest cells, in wild-type and Elongin A/
embryos. Expression of Sox10 was markedly decreased in the
cranial ganglia and DRG of Elongin A/ embryos (Figures 1C
and S1C), suggesting a role for Elongin A in migration and/or
differentiation of neurogenic neural crest cells both in cranial
and trunk regions.
In contrast to neural crest cells, ectodermal placodes start as
a common thickened primordium of ectodermal origin that then
segregates into various placodal territories with the help of
surrounding signals (Schlosser, 2006). The time course of pla-
code formation correlates with sequential expression of marker
genes specifying each differentiation step. Descendants of
Pax8-expressing cells in both the otic and epibranchial placode
regions (Figure 1C) give rise to the vestibulocochlear and genic-
ulate (distal facial) ganglia and their cranial nerves (Bouchard
et al., 2004). We used Pax8 expression as a marker for the form-
ing otic and epibranchial placodes. Comparable expression
patterns of Pax8 were observed in the coalescing epibranchial
placodes in wild-type and Elongin A/ embryos (Figures 1C
and S1C), suggesting that loss of Elongin A does not affect spec-
ification of otic and epibranchial placodes.
Neurogenin1, Neurogenin2, and NeuroD1 encode proneural
basic-helix-loop-helix (bHLH) transcription factors that are re-
quired for sensory neurogenesis (Bertrand et al., 2002). Neuro-
genin1 is required for development of neurons of neural crest,
trigeminal, and otic placodal origin, whereas Neurogenin2 is
required for that originating from epibranchial placodes (Fode
et al., 1998; Ma et al., 1998). Expression of Neurogenin1 in the
trigeminal ganglia and trunk neural tube was significantly de-
creased; however, only a slight decrease of the Neurogenin2Cell Reexpression in the geniculate and petrosal (distal glossopharyng-
eal) ganglia was observed in Elongin A/ embryos (Figures 1C
and S1C).NeuroD1, a downstream transcriptional target of Neu-
rogenins that is typically expressed in ganglionic cells (Fode
et al., 1998; Ma et al., 1998), was obviously reduced in the
trigeminal ganglia of Elongin A/ embryos (Figures 1C and
S1C), suggesting that the total number of neurons in these
regions was decreased in Elongin A/ embryos. Expression
of Mash1, which encodes a proneural bHLH factor required
for autonomic but not sensory neurogenesis (Bertrand et al.,
2002), was, however, unchanged betweenwild-type and Elongin
A/ embryos (Figure 1C). Taken together, the observations that
(1) in Elongin A/ embryos, formation of cranial ganglia and
DRG was severely impaired, and (2) expression of Sox10 and
Neurogenin1 in those regions was obviously affected by the
loss of Elongin A suggest the possibility that Elongin A plays
a critical role in the development of the sensory nervous system
at least in part by regulating the differentiation processes of
neural crest cells.
Elongin A/ ESCs Display Impaired Ability to
Differentiate into Neurons
We next tested the ability of Elongin A/ ESCs to form neuronal
cell types. Elongin A+/+ and Elongin A/ ESCs were grown in
suspension culture for 4 days without leukemia inhibitory factor
(LIF) and for an additional 4 days with RA (4/4+ protocol) to
induce embryoid body (EB) formation (Figure S1D). As shown
in Figures 1D and S1E, the expression of bIII-tubulin and of Nes-
tin, a marker characteristic of neural progenitor cells, but not of
glial fibrillary acidic protein (GFAP) or 20, 30-cyclic nucleotide
30-phosphodiesterase (CNPase), which are markers of astro-
cytes and oligodendrocytes, respectively, was significantly in-
creased upon RA treatment in Elongin A+/+ EBs. In contrast,
expression of Nestin and bIII-tubulin was almost unaltered by
RA in Elongin A/ EBs. Dissociated EBs were also analyzed
3 days later for their morphology and for expression of bIII-
tubulin and microtubule-associated protein 2 (MAP2), a marker
of postmitotic neurons. The Elongin A+/+ cultures displayed char-
acteristic neuronal morphology: some cells were aggregated
with each other, and their cell bodies and many dendrites were
stained strongly with both bIII-tubulin and MAP2 (Figure 1E,
upper panels), whereas almost none of the Elongin A/ cells
showed such characteristics (Figure 1E, lower panels). Cell
proliferation and apoptosis in EBs were also examined by Ki67
staining and TUNEL assays, respectively. No significant differ-
ence in the number of TUNEL+ cells was observed between
Elongin A+/+ and Elongin A/ EBs in the absence or presence
of RA (Figure 1F), whereas an RA-induced increase in the
number of Ki67+ cells was only observed in Elongin A+/+ EBs
(Figure 1G). Together, these results indicate that Elongin A
makes a significant contribution to RA-induced neuronal differ-
entiation of ESCs, most likely by promoting an early stage of
the differentiation cascade.
Elongin A Is Involved in RA-Induced Expression of
a Subset of Neurogenesis-Related Genes
To identify potential Elongin A targets during neuronal differenti-
ation of ESCs, a cDNA microarray analysis comparing Elonginports 2, 1129–1136, November 29, 2012 ª2012 The Authors 1131
Figure 2. Elongin A Is Involved in RA-
Induced Expression of a Subset of Neuro-
genesis-Related Genes
(A) Elongin A/ ESCs and Elongin A+/+ ESCs were
subjected to 4/4+ protocol for EB formation and
were analyzed for the expression of various genes
indicated in the figure by semiquantitative RT-
PCR. See also Table S3.
(B) Effect of Elongin A on pol II occupancy on
the Neurogenin1, Neurogenin2, Hoxa7, or GAPDH
gene in the presence or absence of RA induction
in EBs. Ig, IgG control, Specific ab, specific anti-
body. ChIP/Input is average from two biological
replicates; error bars show data range. See also
Table S4.A/ and Elongin A+/+ EBs was performed. Of all the genes
analyzed, 540 are known to be functionally related to neurogen-
esis, out of which 46 (8.5%) were significantly downregulated in
Elongin A/ EBs (Table S1). Moreover, a Gene Ontology (GO)
analysis of the list of downregulated transcripts revealed a signif-
icant enrichment for genes whose products are involved in
processes of nervous system development, such as neuron pro-
jection morphogenesis and development, axonogenesis, cell
morphogenesis involved in neuronal differentiation, and neu-
ronal development and differentiation (Table S2). These findings
are consistent with the neuronal defects observed in vivo in
Elongin A/ embryos.
To verify the results of the microarray analysis and to confirm
that the defect in RA-induced upregulation of these genes is truly
dependent on the loss of Elongin A, Elongin A/ and Elongin
A+/+ ESCs were subjected to 4/4+ protocol for EB formation
and analyzed for the expression of mRNA by semiquantitative
RT-PCR. As shown in Figure 2A, RA-induced expression of
Neurogenin1, Neurogenin2, NeuroD4, and Hoxa7 was signifi-
cantly impaired only in Elongin A/ EBs. Whereas Neurogenins
are involved in initiating neurogenesis, NeuroD4 is involved in
mediating terminal differentiation (Bertrand et al., 2002). Hoxa71132 Cell Reports 2, 1129–1136, November 29, 2012 ª2012 The Authorsis a member of a paralogous group of
homeobox-containing gene that con-
trols region-specific differentiation during
development and plays a regulatory role
in CNS patterning and cell specifica-
tion (Akin and Nazarali, 2005). In con-
trast, RA-induced expression of Mash1,
Pax6, a paired homeodomain transcrip-
tion factor gene required for neurogene-
sis (Simpson and Price, 2002), Nestin,
and Cyp26B1, which encodes a cyto-
chrome-P450 enzyme that catabolizes
RA (Maden, 2002), was normal in both
Elongin A/ and Elongin A+/+ EBs. Simi-
larly, the expression of Id1 and Id3, which
code for negative HLH factors that inhibit
the transcriptional activity of neurogenic
bHLH transcription factors (Bertrand
et al., 2002) and are not RA regulatory
targets, was normal in Elongin A/ EBs.
We then analyzed pol II occupancy on the Neurogenin1, Neu-
rogenin2, andHoxa7 genes in EBs in the presence or absence of
RA treatment using chromatin immunoprecipitation (ChIP). Very
little pol II (either total or a form of pol II phosphorylated on Ser5
of the CTD) could be detected on the Neurogenin2, Neuroge-
nin1, and Hoxa7 genes in the absence of RA in Elongin A+/+
and Elongin A/ EBs. The amount of both total and Ser5-phos-
phorylated pol II detected in the promoters and the bodies of
these genes was dramatically increased in the presence of RA
in Elongin A+/+ EBs, but not in Elongin A/ EBs (Figure 2B).
Taken together, these findings indicate that Elongin A contrib-
utes to RA-induced transcription of a subset of genes function-
ally related to neurogenesis.
Identification of Elongin A Mutants that Differentially
Affect E3 Ubiquitin Ligase or Transcription Elongation
Activities
Immediately downstream of its BC box, Elongin A contains se-
quences similar to the canonical Cul5 box consensus fxxLPf
Pxxfxx[Y/F][L/I], which in other BC box proteins has been
shown to specify assembly into Cul5-based ubiquitin ligases
(Mahrour et al., 2008) (Figure 3A). We have previously shown
Figure 3. Identification of Elongin A Mutations that Selectively Inactivate Either Its Rpb1 Ubiquitylation or Transcriptional Elongation
Activities
(A) Alignment of amino acid sequences of SOCS box proteins. The BC box and Cul5 box are indicated (boxed). Identical (black) and similar (gray) amino acids are
shaded. Asterisks indicate C termini. Sequences are of the human proteins with the exception of Elongin A. Sequences of the SOCS box of Elongin A are perfectly
conserved between rat and human and correspond to amino acids 550–588 in human Elongin A. The canonical BC box and Cul5 box sequences are indicated
below each alignment. NTD, N-terminal domain.
(B) N-terminal, C-terminal, and Cul5 box point mutants of Elongin A analyzed in this study. On the right, the results of the assays shown in (D) and (E) are pre-
sented. Some of results were originated from previously published work (Aso et al., 1996; Yasukawa et al., 2008). N.D., not determined;WT, wild-type. VPmut, VL
mut, and VVPL mut represent Elongin A[V571A;P572A], Elongin A[V568A;L576A], and Elongin A[V568A;V571A;P572A;L576A], respectively.
(C) Sf9 cells were coinfected with the baculoviruses indicated in the figure. Anti-HA immunoprecipitation was performed as described under Experimental
Procedures. Total cell lysates and anti-HA immunoprecipitates were separated by SDS-PAGE and immunoblotted with the indicated antibodies. Arrowheads
indicate Elongin A(400–773). The asterisk indicates the IgG heavy chain. IP, immunoprecipitation.
(D) Lysates from Sf9 cells infected with the indicated baculoviruses were immunoprecipitated with anti-HA antibody and were assayed for their ability to activate
Rpb1 ubiquitylation as described under Experimental Procedures. Samples were analyzed on 6% SDS-PAGE and processed for western blotting (WB) with H14
antibody.
(E) The oligo (dC)-tailed template assays were performed as described under Experimental Procedures in the absence or presence of wild-type and indicated
Elongin Amutants complexed with Elongin BC. The concentration of Elongin complexes was adjusted so that Elongin A was present in reaction mixtures at either
6 or 18 nM.that amino acid sequences between residues 521 and 680 of
Elongin A, which include both the BC box and Cul5 box
consensus sequences, are required for both Rpb1 ubiquitylation
and transcriptional elongation activities (Aso et al., 1996; Yasu-
kawa et al., 2008). To investigate the possibility that these two
activities are separable by further mutagenesis, we constructed
three Cul5 box point mutants and four more C-terminal deletion
mutants of Elongin A. Elongin A[V571A;P572A] (Elongin A-VP),
Elongin A[V568A;L576A] (Elongin A-VL), and Elongin A[V568A;
V571A;P572A;L576A] (Elongin A-VVPL) contain alanine substitu-
tions of predicted key Cul5 box residues. Elongin A(1–677), Elon-
gin A(1–674), Elongin A(1–670), or Elongin A(1–660) each containCell Readditional small C-terminal deletions that we expected might
affect both activities (Figure 3B).
Sf9 cells were coinfected with various combinations of bacu-
loviruses encoding Elongins B and C, myc-Rbx2, HA-Cul5, and
Flag-tagged wild-type or mutant Elongin A. Cul5-containing
ubiquitin ligase complexes were immunoprecipitated from cell
lysates with anti-HA antibody and analyzed for (i) the relative
amount of Elongin A in each complex by immunoblotting and
(ii) their abilities to activate Rpb1 ubiquitylation in vitro. As shown
in Figures 3B and 3C, the Elongin A Cul5 box mutants Elongin
A-VP, Elongin A-VL, and Elongin A-VVPL were severely impaired
in their abilities to assemble into ubiquitin ligase complexes.ports 2, 1129–1136, November 29, 2012 ª2012 The Authors 1133
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Figure 4. The Elongin A Transcriptional Elongation, but Not Its
Rpb1 Ubiquitylation, Activity Is Required for Elongin A-Dependent
Neuronal Differentiation and Gene Regulation
(A) Expression levels of Elongin A in Elongin A+/+ ESCs or Elongin A/ ESCs
transfected with expression vectors encoding wild-type or various mutant
Elongin A were analyzed by western blotting with anti-Elongin A (left panel) or
anti-Flag antibody (right panel). VP mut represents Elongin A[V571A;P572A].
The asterisk indicates nonspecific bands.
(B and C) Various ESC clones in (A) were subjected to 4/4+ protocol for EB
formation and were analyzed for the expression of bIII-tubulin or a-tubulin by
western blotting (B) and for the expression of genes indicated in the figure by
semiquantitative RT-PCR (C).Consistent with this observation, Cul5 complexes from cells
expressing these Elongin Amutants failed to activate Rpb1 ubiq-
uitylation above the low background level observed in the
absence of Elongin A. Furthermore, the C-terminal deletions
Elongin A(1–670) and Elongin A(1–660), which can assemble
into Cul5 complexes, also failed to activate Rpb1 ubiquitylation
above background. In contrast, the remaining C-terminal dele-
tion mutants, Elongin A(1–677) and Elongin A(1–674), preserved
levels of ubiquitylation activity similar to that of wild-type Elongin
A (Figures 3B and 3D).
The relative transcriptional elongation activities of the wild-
type and mutant Elongin As complexed with Elongin BC were
then compared using the oligo(dC)-tailed template assay. In
the experiment shown in Figure 3E, the 135-nucleotide tran-
scripts were chased for 4.5 min with a limiting concentration of
UTP in the presence or absence of equivalent amounts of puri-
fied Elongin ABC complexes. Elongin ABC complexes contain-
ing Elongin A mutants Elongin A-VL, Elongin A-VVPL, Elongin
A(1–677), Elongin A(1–674), and Elongin A(1–670) were pro-
foundly impaired in their abilities to stimulate elongation by pol
II. However, Elongin ABC complexes containing Elongin A-VP
exhibited a level of activity comparable to that of the wild-type
Elongin ABC complex.
The Elongin A Transcriptional Elongation, but Not Its
Rpb1 Ubiquitylation, Activity Is Required for Elongin
A-Dependent Neuronal Differentiation and Gene
Regulation
To examine whether the reintroduction of Elongin A into Elongin
A/ ESCs is able to rescue their neuronal differentiation, and if
so, which domain of Elongin A is required for this activity, we
transfected cDNAs encoding wild-type and various mutant Elon-
gin As into Elongin A/ ESCs (Figure 4A). These ESC clones
were subjected to 4/4+ protocol for EB formation and tested
for RA-inducible expression of the neuronal marker bIII-tubulin.
As shown in the western blots of Figure 4B, neither Elongin A
[D(546–565)], which lacks its BC box and is defective in both
transcriptional elongation and E3 ubiquitin ligase activities (Aso
et al., 1996; Yasukawa et al., 2008), nor Elongin A(1–674) was
able to rescue RA-induced expression of the neuronal marker
bIII-tubulin. In contrast, RA-induced bIII-tubulin expression was
restored in cells expressing the ubiquitylation-defective mutant
Elongin A-VP.
In further experiments, we tested the ability of wild-type and
mutant Elongin As to rescue RA-induced expression ofNeuroge-
nin1, Neurogenin2, NeuroD4, and Hoxa7mRNAs in EBs derived
from Elongin A/ ESCs. As shown in Figure 4C, a comparable
level ofRA-inducedexpression of these four geneswasobserved
in EBs derived from ESCs transfected with wild-type Elongin A
and Elongin A-VP, but not in EBs derived from ESCs transfected
with Elongin A[D(546–565)] and Elongin A(1–674). In contrast, the
expression of Cyp26B1 was induced by RA regardless of the
transfected Elongin A, and that of Id1 was almost unaltered
regardless of either the transfected Elongin A or RA treatment.
Taken together, these results argue that (1) mammalian Elon-
gin A contributes to neuronal differentiation in ESCs, at least in
part by regulating RA-induced expression of genes such asNeu-
rogenin1, Neurogenin2, NeuroD4, and Hoxa7, and (2) Elongin A1134 Cell Reports 2, 1129–1136, November 29, 2012 ª2012 The Auttranscriptional elongation activity, but not its E3 ubiquitin ligase
activity, is critical for these functions.
DISCUSSION
RA signaling plays a key role in vertebrate embryogenesis. The
embryonic distribution of RA correlates with neuronal differenti-
ation and positional specification in the developing CNS (Maden,
2002). RA is also an important extrinsic inductive signal that can
be used to induce neuronal differentiation of mouse ESCs in vitrohors
(Bain et al., 1995). Hundreds of genes have been shown to be
regulated by RA during the processes of neuronal differentiation
and neurite outgrowth, including those encoding transcription
factors, extracellular proteins, neurotransmitters, growth factors,
and cell surface receptors (Maden, 2002). Here, we have shown
that (1) Elongin A/ embryos exhibit reduced number in subpop-
ulationsof neural progenitors anddifferentiatedneurons through-
out the peripheral nervous system, (2) RA-induced neuronal
differentiation is severely impaired in Elongin A/ ESCs, and (3)
Elongin A is required for transcription of a subset of RA-induced
genes with roles in neuronal development and differentiation.
How might Elongin A participate in RA-induced pol II tran-
scription? Our rescue experiments demonstrate that a func-
tional Elongin A elongation activation domain is needed to
rescue the neuronal differentiation and gene expression defects
of Elongin A/ ESCs; however, an Elongin A mutant that does
not assemble into Cul5-containing ubiquitin ligase complexes
and hence does not support Rpb1 ubiquitylation activity can still
rescue these defects. Although ubiquitylation of pol II was origi-
nally detected as a response to DNA damage (Bregman et al.,
1996), more recent results suggest that pol II ubiquitylation
during transcript elongation is a frequent event that can occur
in the absence of DNA damage; indeed, pol II ubiquitylation is
now thought to be a general response to paused or arrested
elongation complexes (Svejstrup, 2007). Therefore, Rpb1 ubiqui-
tylation evoked by Elongin A and/or other ubiquitin ligases has
been proposed to be a mechanism that ensures the overall
efficiency of transcript elongation either by (1) reactivating the
elongation complexes by recruiting 19S subparticle of the pro-
teasome, which in turn stimulates transcription elongation (Fer-
dous et al., 2001), or (2) removing paused or arrested pol II
from the DNA by proteasome-mediated degradation, thereby
enabling the next pol II to transcribe the gene (Svejstrup, 2007).
Our results, however, are most consistent with the model that
the elongation stimulatory activity of Elongin A, but not Elongin
A-dependent pol II ubiquitylation, is required for production of
full-length transcripts essential to rescue the neuronal differenti-
ation defect of Elongin A/ ESCs. In this scenario, the require-
ment for the Rpb1 ubiquitylation activity of Elongin A might be
gene specific and would depend on the nucleotide sequences
of the genes and, perhaps, on the structure and number of sites
causing pausing or arrest of pol II. Importantly, our observations
do not rule out the possibility that Rpb1 ubiquitylationmight have
amore general role because pol II is likely to be targeted for ubiq-
uitylation by more than one E3 ubiquitin ligase in metazoan cells
(Svejstrup, 2007; Yasukawa et al., 2008; Harreman et al., 2009).
Recent genome-wide studies have demonstrated that a large
number of developmentally regulated genes contain paused pol
II at their promoters and that a significant fraction of these
encode transcription factors involved in neurogenesis and ecto-
dermal development or components of cell signaling pathways
(Zeitlinger et al., 2007). Thus, it is now believed that the transition
of pol II from the promoter-proximal early to the productive elon-
gation stage of transcription is a key regulatory step that facili-
tates rapid temporal and spatial changes in gene expression
during differentiation and development in metazoans.
Although we have not yet succeeded in generating antibodies
suitable for ChIP of Elongin A in mouse ESCs, Gerber et al.Cell Rehave reported that the Drosophila ortholog of Elongin A colocal-
izes with pol II at sites of active transcription on polytene
chromosomes and that it is required, not only for proper meta-
morphosis, but also for heat shock gene expression (Gerber
et al., 2004, 2005). More recently, Chopra et al. (2009) have pre-
sented evidence that in Drosophila embryos, the elongation
factors P-TEFb, which relieves DSIF- and NELF-dependent pol
II pausing (reviewed in Conaway et al., 2000; Shilatifard et al.,
2003), and Elongin A are essential for optimal expression of at
least a subset of Drosophila Hox genes and that mutations in
the CDK9 subunit of P-TEFb and Elongin A exhibited additive
effects particularly on the reduction in Ultrabithorax activity.
Taken together with the findings reported here, these observa-
tions raise the possibilities that (1) Elongin A is a limiting factor
for optimal expression of a subset of genes that undergo tran-
sient high-level expression in response to external signals and/
or stimuli, and (2) Elongin A might function together with other
elongation factors such as P-TEFb in a nonredundant, gene-
specific manner during transcription.
Although our data implicate Elongin A’s transcription elonga-
tion activity in RA-induced activation of transcription of a subset
of neurogenic genes, the precise biochemical mechanism by
which Elongin A participates in RA-induced transcriptional acti-
vation remains to be determined. Our ChIP data indicate that
loss of Elongin A dramatically decreases pol II occupancy at
both the transcribed regions and the promoters of several
genes. We cannot rule out the possibility that these changes
are secondary to Elongin A-dependent control of other transcrip-
tional regulatory factors; however, an alternative possibility is
that Elongin A not only contributes to elongation control but
also affects transcription by enhancing pol II recruitment and/
or stability of very early transcription complexes. Interestingly,
results of a recent study support just such a role for another
transcription elongation factor, eleven-nineteen lysine-rich in
leukemia (ELL) (Byun et al., 2012).
In summary, our results argue that the transcription elongation
activity of mammalian Elongin A is required for neuronal differen-
tiation and development and has a crucial role in RA-induced
transcription by pol II of a subset of genes critical for neurogen-
esis. In the future, it will be of considerable interest to explore in
more detail how Elongin A’s elongation activity contributes to
gene regulation and to determine why some, but not all, RA-
inducible genes are particularly dependent on Elongin A for their
activation.
EXPERIMENTAL PROCEDURES
ESC Culture, Cell Lines, and Differentiation of ESCs
ESC culture and generation of Elongin A+/+ and Elongin A/ ESC clones ex-
pressing wild-type or mutant Elongin A were as described (Yasukawa et al.,
2008). EB formation was carried out essentially as described by Bain et al.
(1995).
Immunocytochemistry, Histological Analyses, RNA In Situ
Hybridization, and ChIP
Immunocytochemistry, histological analyses, RNA in situ hybridization, and
ChIP were performed using standard methods. See Extended Experimental
Procedures for details. All animal care and experiments conformed to the
Guidelines for Animal Experiments of Kochi University and were approved
by the Animal Research Committee of Kochi University.ports 2, 1129–1136, November 29, 2012 ª2012 The Authors 1135
Production of Recombinant Proteins, Immunoprecipitation,
Western Blotting, and Assays of Ubiquitylation and Transcription
In Vitro
Expression of recombinant proteins in E. coli and Sf9 cells, immunoprecipita-
tion, immunoblotting, and in vitro ubiquitylation and transcription were per-
formed essentially as described (Aso et al., 1995; Yasukawa et al., 2008)
and are detailed in the Extended Experimental Procedures.
RT-PCR, Microarray, and GO Analyses
RT-PCR and microarray analyses were performed essentially as described by
Miyata et al. (2007) and are detailed in the Extended Experimental Procedures.
Primer sets used are listed in Table S3. The GO analysis of biological
processes was performed using the DAVID Bioinformatics Database (http://
david.abcc.ncifcrf.gov).
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